243 related articles for article (PubMed ID: 15897565)
1. Patterns of gene expression that characterize long-term survival in advanced stage serous ovarian cancers.
Berchuck A; Iversen ES; Lancaster JM; Pittman J; Luo J; Lee P; Murphy S; Dressman HK; Febbo PG; West M; Nevins JR; Marks JR
Clin Cancer Res; 2005 May; 11(10):3686-96. PubMed ID: 15897565
[TBL] [Abstract][Full Text] [Related]
2. Prediction of optimal versus suboptimal cytoreduction of advanced-stage serous ovarian cancer with the use of microarrays.
Berchuck A; Iversen ES; Lancaster JM; Dressman HK; West M; Nevins JR; Marks JR
Am J Obstet Gynecol; 2004 Apr; 190(4):910-25. PubMed ID: 15118612
[TBL] [Abstract][Full Text] [Related]
3. Gene expression profiling of advanced-stage serous ovarian cancers distinguishes novel subclasses and implicates ZEB2 in tumor progression and prognosis.
Yoshihara K; Tajima A; Komata D; Yamamoto T; Kodama S; Fujiwara H; Suzuki M; Onishi Y; Hatae M; Sueyoshi K; Fujiwara H; Kudo Y; Inoue I; Tanaka K
Cancer Sci; 2009 Aug; 100(8):1421-8. PubMed ID: 19486012
[TBL] [Abstract][Full Text] [Related]
4. Expression of carbohydrate antigens in advanced-stage ovarian carcinomas and their metastases-A clinicopathologic study.
Davidson B; Gotlieb WH; Ben-Baruch G; Kopolovic J; Goldberg I; Nesland JM; Berner A; Bjåmer A; Bryne M
Gynecol Oncol; 2000 Apr; 77(1):35-43. PubMed ID: 10739688
[TBL] [Abstract][Full Text] [Related]
5. Alphav integrin expression is a novel marker of poor prognosis in advanced-stage ovarian carcinoma.
Goldberg I; Davidson B; Reich R; Gotlieb WH; Ben-Baruch G; Bryne M; Berner A; Nesland JM; Kopolovic J
Clin Cancer Res; 2001 Dec; 7(12):4073-9. PubMed ID: 11751504
[TBL] [Abstract][Full Text] [Related]
6. Differential gene expression profiles between tumor biopsies and short-term primary cultures of ovarian serous carcinomas: identification of novel molecular biomarkers for early diagnosis and therapy.
Bignotti E; Tassi RA; Calza S; Ravaggi A; Romani C; Rossi E; Falchetti M; Odicino FE; Pecorelli S; Santin AD
Gynecol Oncol; 2006 Nov; 103(2):405-16. PubMed ID: 16725184
[TBL] [Abstract][Full Text] [Related]
7. Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome.
Tothill RW; Tinker AV; George J; Brown R; Fox SB; Lade S; Johnson DS; Trivett MK; Etemadmoghadam D; Locandro B; Traficante N; Fereday S; Hung JA; Chiew YE; Haviv I; ; Gertig D; DeFazio A; Bowtell DD
Clin Cancer Res; 2008 Aug; 14(16):5198-208. PubMed ID: 18698038
[TBL] [Abstract][Full Text] [Related]
8. Screening for genes associated with ovarian cancer prognosis.
Chang XH; Zhang L; Yang R; Feng J; Cheng YX; Cheng HY; Ye X; Fu TY; Cui H
Chin Med J (Engl); 2009 May; 122(10):1167-72. PubMed ID: 19493465
[TBL] [Abstract][Full Text] [Related]
9. Indoleamine 2,3-dioxygenase serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells.
Okamoto A; Nikaido T; Ochiai K; Takakura S; Saito M; Aoki Y; Ishii N; Yanaihara N; Yamada K; Takikawa O; Kawaguchi R; Isonishi S; Tanaka T; Urashima M
Clin Cancer Res; 2005 Aug; 11(16):6030-9. PubMed ID: 16115948
[TBL] [Abstract][Full Text] [Related]
10. Caveolin-1 expression in advanced-stage ovarian carcinoma--a clinicopathologic study.
Davidson B; Nesland JM; Goldberg I; Kopolovic J; Gotlieb WH; Bryne M; Ben-Baruch G; Berner A; Reich R
Gynecol Oncol; 2001 May; 81(2):166-71. PubMed ID: 11330944
[TBL] [Abstract][Full Text] [Related]
11. Genetic analysis of early- versus late-stage ovarian tumors.
Shridhar V; Lee J; Pandita A; Iturria S; Avula R; Staub J; Morrissey M; Calhoun E; Sen A; Kalli K; Keeney G; Roche P; Cliby W; Lu K; Schmandt R; Mills GB; Bast RC; James CD; Couch FJ; Hartmann LC; Lillie J; Smith DI
Cancer Res; 2001 Aug; 61(15):5895-904. PubMed ID: 11479231
[TBL] [Abstract][Full Text] [Related]
12. Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer.
Zorn KK; Bonome T; Gangi L; Chandramouli GV; Awtrey CS; Gardner GJ; Barrett JC; Boyd J; Birrer MJ
Clin Cancer Res; 2005 Sep; 11(18):6422-30. PubMed ID: 16166416
[TBL] [Abstract][Full Text] [Related]
13. Use of gene expression profiles to stage concurrent endometrioid tumors of the endometrium and ovary.
Guirguis A; Elishaev E; Oh SH; Tseng GC; Zorn K; DeLoia JA
Gynecol Oncol; 2008 Feb; 108(2):370-6. PubMed ID: 18083218
[TBL] [Abstract][Full Text] [Related]
14. Gene expression profiling of epithelial ovarian tumours correlated with malignant potential.
Warrenfeltz S; Pavlik S; Datta S; Kraemer ET; Benigno B; McDonald JF
Mol Cancer; 2004 Oct; 3():27. PubMed ID: 15471544
[TBL] [Abstract][Full Text] [Related]
15. Microarray expression identification of differentially expressed genes in serous epithelial ovarian cancer compared with bulk normal ovarian tissue and ovarian surface scrapings.
Grisaru D; Hauspy J; Prasad M; Albert M; Murphy KJ; Covens A; Macgregor PF; Rosen B
Oncol Rep; 2007 Dec; 18(6):1347-56. PubMed ID: 17982616
[TBL] [Abstract][Full Text] [Related]
16. Ovarian cancer tumor infiltrating T-regulatory (T(reg)) cells are associated with a metastatic phenotype.
Barnett JC; Bean SM; Whitaker RS; Kondoh E; Baba T; Fujii S; Marks JR; Dressman HK; Murphy SK; Berchuck A
Gynecol Oncol; 2010 Mar; 116(3):556-62. PubMed ID: 20006900
[TBL] [Abstract][Full Text] [Related]
17. Genomic expression patterns distinguish long-term from short-term glioblastoma survivors: a preliminary feasibility study.
Marko NF; Toms SA; Barnett GH; Weil R
Genomics; 2008 May; 91(5):395-406. PubMed ID: 18343632
[TBL] [Abstract][Full Text] [Related]
18. Analysis of gene expression in early-stage ovarian cancer.
Marchini S; Mariani P; Chiorino G; Marrazzo E; Bonomi R; Fruscio R; Clivio L; Garbi A; Torri V; Cinquini M; Dell'Anna T; Apolone G; Broggini M; D'Incalci M
Clin Cancer Res; 2008 Dec; 14(23):7850-60. PubMed ID: 19047114
[TBL] [Abstract][Full Text] [Related]
19. Patterns of gene expression in different histotypes of epithelial ovarian cancer correlate with those in normal fallopian tube, endometrium, and colon.
Marquez RT; Baggerly KA; Patterson AP; Liu J; Broaddus R; Frumovitz M; Atkinson EN; Smith DI; Hartmann L; Fishman D; Berchuck A; Whitaker R; Gershenson DM; Mills GB; Bast RC; Lu KH
Clin Cancer Res; 2005 Sep; 11(17):6116-26. PubMed ID: 16144910
[TBL] [Abstract][Full Text] [Related]
20. High-risk ovarian cancer based on 126-gene expression signature is uniquely characterized by downregulation of antigen presentation pathway.
Yoshihara K; Tsunoda T; Shigemizu D; Fujiwara H; Hatae M; Fujiwara H; Masuzaki H; Katabuchi H; Kawakami Y; Okamoto A; Nogawa T; Matsumura N; Udagawa Y; Saito T; Itamochi H; Takano M; Miyagi E; Sudo T; Ushijima K; Iwase H; Seki H; Terao Y; Enomoto T; Mikami M; Akazawa K; Tsuda H; Moriya T; Tajima A; Inoue I; Tanaka K;
Clin Cancer Res; 2012 Mar; 18(5):1374-85. PubMed ID: 22241791
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]